stockrow
Friday 6 November 2026
Export MIRM’s income statement to Excel — free account
Mirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.
- Revenue
- +39.6%
- EPS
- −1,136.8%
- Free cash flow
- −114.2%
- Total debt
- +136.4%
Quarter to September 2026, against a year earlier
93.82
0.28
+0.30%
Follow MIRM
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
8.35 | 12.00 | 9.54 | 7.61 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 132.73 | |
P/Operating CF |
(1,299.29) | (167.66) | (23.77) | 653.56 | |
P/B ratio |
0.00 | 0.00 | 22.42 | 12.60 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 73.74 | |
EV/Sales |
8.88 | 12.51 | 9.41 | 7.47 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 1,011.60 | |
EV/Operating CF |
(21.97) | (34.02) | (31.35) | 69.71 | |
EV/FCF |
(19.29) | (28.24) | (26.47) | 130.27 | |
Quick Ratio |
1.87 | 2.62 | 1.90 | 2.46 | |
Current Ratio |
2.07 | 2.86 | 2.09 | 2.67 | |
Net Debt/EBITDA |
(6.88) | (8.92) | 0.10 | (37.84) | |
Debt/Assets |
71.23% | 71.78% | 34.82% | 36.76% | |
Debt/Equity |
(13.50) | (71.97) | 1.28 | 0.98 | |
Asset Turnover |
0.74 | 0.70 | 0.72 | 0.69 | |
Operating CF/Net income |
0.11 | 0.66 | 0.29 | (1.06) | |
Capex/Depreciation |
(0.17) | (3.30) | (1.46) | (0.09) | |
Interest Coverage |
(37.20) | (16.25) | (218.33) | (1.27) | |
Research and Development Expense of Revenue |
65.38% | 60.69% | 515.51% | 34.32% | |
Selling, General and Administrative Expense of Revenue |
47.85% | 46.23% | 60.25% | 49.77% | |
Intangible Assets out of Total Assets |
0.27 | 0.24 | 0.29 | 0.31 | |
Share Based Compensation of Revenue |
17.94% | 17.35% | 22.64% | 12.77% | |
Graham Net Nets |
(0.09) | (0.06) | (0.01) | 0.01 | |
Graham Number |
16.83 | 7.33 | 0.00 | 0.00 | |
Earnings Yield |
(17.81%) | (12.42%) | (14.72%) | (0.60%) | |
Free Cash Flow Yield |
(5.51%) | (3.69%) | (3.73%) | 0.75% | |
Revenue per Share |
2.83 | 2.78 | 2.72 | 2.97 | |
Operating CF per Share |
(0.07) | (0.70) | (3.89) | 0.12 | |
Capex per Share |
(0.02) | (0.39) | (0.18) | (0.01) | |
Free Cash Flow per Share |
(0.09) | (1.09) | (4.07) | 0.11 | |
Cash per Share |
5.70 | 6.92 | 6.56 | 7.64 | |
Shareholders Equity per Share |
(0.83) | (0.16) | 4.12 | 6.27 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.83) | (0.16) | 4.12 | 6.27 | |
Free Cash Flow |
(5.62) | (69.27) | (239.43) | 5.47 | |
Working Capital |
303.55 | 413.52 | 296.61 | 343.89 | |
Capital Expenditures |
(1.30) | (25.02) | (10.66) | (0.60) | |
Net Current Asset Value |
(494.17) | (419.09) | (78.99) | 21.56 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.14 | 0.07 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
131.74 | 126.10 | 114.48 | 100.81 | |
Average Payables |
12.91 | 20.54 | 35.52 | 12.12 | |
Average Inventory |
24.75 | 24.36 | 23.97 | 23.65 | |
Average Assets |
905.86 | 885.40 | 790.58 | 756.78 | |
Average Common Equity |
118.93 | 122.37 | 237.88 | 270.17 |
Columns are period end dates · fundamentals updated 5 Nov 2026